Eli Lilly Writes a Check. AC Immune Surges 15%. Is This Strategy or Spare Change? Apr 7, 2026 Life Science
Wave Life Sciences’ Weight Loss Drug Phase 1 Clinical Data Triggers Stock Volatility, Yet Differentiated Path Still Shows Promise Apr 1, 2026 Life Science
Impressive Performance Yet Low Stock Price, Can Eli Lilly Usher in a Turning Point with Medicare Coverage? Mar 31, 2026 Life Science
This Popular ETF Quietly Boosted Its Healthcare Stake – High-Yield Dividend Stocks Are the New Favorite Mar 31, 2026 Life Science
Viking Therapeutics Approaches Make-or-Break Moment as Key GLP-1 Data Looms Mar 29, 2026 Life Science
Approved Catalyst Fuels Market Movement, Corcept Therapeutics Leads Healthcare Sector This Week Mar 27, 2026 Life Science
After Surging Over 100% in a Year, Executives Reduce Holdings Amid Adaptive Biotech’s Strong Performance Mar 27, 2026 Life Science
High Volatility, High Reward: Two Biotech Stocks for the Risk-Tolerant Investor Mar 26, 2026 Life Science
Under the Spotlight of GLP-1, the Hidden Risks of Eli Lilly’s High Valuation Cannot Be Ignored Mar 26, 2026 Life Science
After Five Years of Sluggish Performance, Pfizer Finds Renewed Hope in High Dividends and Clinical Data Mar 25, 2026 Life Science
